Premium
Perioperative Administration of Atorvastatin and Simvastatin has Cardioprotective Effects in Type 1 Diabetic Rats
Author(s) -
Crespo Maria J.,
Cruz Nildris,
Quidgley Jose,
Creagh Osmar,
Torres Hector,
Rivera Karines,
Hernandez Cesar,
Casiano Hector
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb621
Subject(s) - medicine , atorvastatin , simvastatin , pravastatin , perioperative , cardiac function curve , ejection fraction , anesthesia , statin , fluvastatin , cardiology , cholesterol , heart failure
Perioperative statin administration has been suggested to improve postoperative cardiovascular outcomes in patients undergoing surgery, but the optimal administration time and the best statin suited to improve postoperative outcomes in diabetics is unknown. In this study, we evaluate by echocardiography the effects of simvastatin (SV, 10 mg/kg/d), pravastatin (PV, 10 mg/kg/d), and atorvastatin (AV, 10 mg/kg/d) on the cardiovascular status of anesthetized streptozotocin (STZ)‐induced diabetic rats with compromised cardiac function. Echocardiographic measurements revealed that 24 hours after administering statins, cardiovascular parameters did not improve. In contrast, daily administration of SV and AV over a one‐week period significantly improved ejection fraction from 44% to 63% with AV, and to 65% with SV (N=9, P<0.05). The cardiac output index also was significantly improved by AV and SV. Only AV increased stroke volume from 0.50±0.08 ml to 0.83±0.13 ml (N=9, P<0.05). Unlike the other statins tested, PV provided no beneficial effects after either 24 hours or one‐week administration. Our results indicate that daily administration of atorvastatin and simvastatin for one week improves cardiac performance in fully anesthetized diabetic rats. This study has strong clinical implications for the improvement of postoperative outcomes in diabetic patients. MBRS‐RISE Grant R25‐GM061838.